Neurotransmitters are the brain's chemical messengers, playing a critical role in transmitting signals between nerve cells (neurons). Among the myriad of neurotransmitters, Gamma-Aminobutyric Acid (GABA) and glutamate are particularly significant due to their essential functions in the brain's overall excitatory and inhibitory balance. Understanding these neurotransmitters and their functions can provide valuable insights into various neurological disorders, including fibromyalgia, myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), and functional neurological disorders (FND).
GABA: The Main Inhibitory Neurotransmitter
What is GABA?
Gamma-Aminobutyric Acid (GABA) is the primary inhibitory neurotransmitter in the brain. Its main function is to reduce neuronal excitability throughout the nervous system.
How Does GABA Work?
GABA exerts its effects by binding to GABA receptors (GABA-A and GABA-B) on the surface of neurons. When GABA binds to these receptors, it typically results in the opening of ion channels that allow negatively charged chloride ions into the neuron, making it more negative and less likely to fire an action potential. This inhibitory effect is crucial for maintaining the brain's overall balance and preventing overexcitation.
Role in Neurological Disorders
GABA dysregulation is implicated in several neurological disorders:
Anxiety Disorders: Low levels of GABA are associated with increased anxiety, as the brain becomes more prone to hyperactivity. Benzodiazepines, a class of anti-anxiety medications, enhance the effect of GABA, thereby producing a calming effect .
Epilepsy: Insufficient GABA activity can lead to uncontrolled neuronal firing, resulting in seizures. Many anti-epileptic drugs work by increasing GABA activity .
Insomnia: GABA plays a role in promoting sleep by inhibiting the neural circuits that promote wakefulness .
Fibromyalgia: Patients with fibromyalgia often exhibit lower levels of GABA, which may contribute to increased pain sensitivity and other symptoms .
ME/CFS: Altered GABAergic function has been observed in ME/CFS, potentially contributing to symptoms such as fatigue and cognitive dysfunction .
FND: Functional neurological disorders may involve GABA dysregulation, leading to the varied and often debilitating symptoms experienced by patients.
Glutamate: The Primary Excitatory Neurotransmitter
What is Glutamate?
Glutamate is the most abundant excitatory neurotransmitter in the brain, responsible for promoting the firing of neurons.
How Does Glutamate Work?
Glutamate binds to several types of receptors, including NMDA, AMPA, and kainate receptors. When glutamate binds to these receptors, it typically causes the opening of ion channels that allow positively charged ions into the neuron, making it more likely to fire an action potential. This excitatory effect is essential for various brain functions, including learning and memory.
Role in Neurological Disorders
Excessive glutamate activity is linked to several neurological conditions:
Alzheimer’s Disease: Overactivation of glutamate receptors, particularly NMDA receptors, can lead to excitotoxicity, where excessive calcium influx damages neurons. This process is believed to contribute to the neuronal death observed in Alzheimer's disease .
Stroke: During a stroke, disrupted blood flow leads to increased release of glutamate, resulting in excitotoxicity and neuronal damage .
Amyotrophic Lateral Sclerosis (ALS): Also known as Lou Gehrig's disease, ALS is associated with increased glutamate levels, which may contribute to the degeneration of motor neurons .
Fibromyalgia: Elevated glutamate levels in certain brain regions have been linked to the heightened pain sensitivity and cognitive symptoms of fibromyalgia .
ME/CFS: Abnormal glutamate signalling has been implicated in ME/CFS, contributing to symptoms such as brain fog and post-exertional malaise .
FND: Imbalances in glutamate may play a role in the development of FND symptoms, influencing motor and cognitive functions .
Other Key Neurotransmitters
Dopamine
Function: Dopamine is involved in reward, motivation, and motor control.
Disorders: Parkinson’s disease (characterized by low dopamine levels), schizophrenia (linked to excessive dopamine activity), and addiction .
Serotonin
Function: Serotonin regulates mood, appetite, and sleep.
Disorders: Depression, anxiety disorders, and migraine headaches are associated with serotonin imbalance. Many antidepressants work by increasing serotonin levels .
Acetylcholine
Function: Acetylcholine is involved in muscle activation, attention, and memory.
Disorders: Alzheimer’s disease and myasthenia gravis are linked to acetylcholine deficits .
Conclusion
Neurotransmitters like GABA and glutamate are essential for maintaining the brain's delicate balance of excitation and inhibition. Dysregulation of these neurotransmitters can lead to various neurological disorders, highlighting the importance of understanding their functions and interactions. This knowledge is particularly relevant for conditions such as fibromyalgia, ME/CFS, and FND, where neurotransmitter imbalances may play a crucial role. Continued research in this area promises to shed light on more effective treatments for these conditions, improving the quality of life for those affected.
References
Goddard, A. W. (2011). Neurobiology of Anxiety. Psychiatry Clin Neurosci, 65(4), 243-257.
Engel, J. (2001). Overview of the mechanisms of epileptogenesis. Epilepsy Research, 50(1-2), 3-8.
Wafford, K. A., & Ebert, B. (2008). GABA-A Receptor Subtypes: The Roles in Sleep and Learning. Current Topics in Medicinal Chemistry, 8(10), 885-895.
Foerster, B. R., Petrou, M., Edden, R. A., Sundgren, P. C., Schmidt-Wilcke, T., Lowe, S. E., ... & Harris, R. E. (2012). Reduced insular gamma-aminobutyric acid in fibromyalgia. Arthritis Rheum, 64(2), 579-583.
Cleare, A. J. (2003). The Neuroendocrinology of Chronic Fatigue Syndrome. Endocrine Reviews, 24(2), 236-252.
Stone, J., Zeman, A., & Sharpe, M. (2010). Functional neurological disorders: the neurological assessment as treatment. Neurophysiol Clin, 40(6), 363-373.
Cacabelos, R., Fernández-Novoa, L., Lombardi, V., Kubota, Y., & Takeda, M. (2019). Cerebrovascular Risk Factors in Alzheimer’s Disease. J Clin Med, 8(6), 913.
Moskowitz, M. A., Lo, E. H., & Iadecola, C. (2010). The science of stroke: Mechanisms in search of treatments. Neuron, 67(2), 181-198.
Spreux-Varoquaux, O., Bensimon, G., Lacomblez, L., Salachas, F., Pradat, P. F., Le Forestier, N., ... & Meininger, V. (2002). Glutamate levels in cerebrospinal fluid in amyotrophic lateral sclerosis: A reappraisal using a new HPLC method with coulometric detection in a large cohort of patients. Journal of the Neurological Sciences, 193(2), 73-78.
Sundgren, P. C., Petrou, M., Harris, R. E., Fan, X., Foerster, B., Mehrotra, N., ... & Clauw, D. J. (2007). Diffusion-weighted imaging of the brain in patients with fibromyalgia. NMR Biomed, 20(4), 448-462.
Volkow, N. D., Wang, G. J., Fowler, J. S., Tomasi, D., & Telang, F. (2009). Addiction: Beyond dopamine reward circuitry. Proceedings of the National Academy of Sciences, 106(45), 18619-18624.
Berger, M., Gray, J. A., & Roth, B. L. (2009). The expanded biology of serotonin. Annual Review of Medicine, 60, 355-366.
Francis, P. T., Palmer, A. M., Snape, M., & Wilcock, G. K. (1999). The cholinergic hypothesis of Alzheimer’s disease: a review of progress. Journal of Neurology, Neurosurgery & Psychiatry, 66(2), 137-147.
Comentários